The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus

Jiang, Yayi; Shui, Jiacheng; Zhang, Boxun; Chin, Jiawei; Yue, Rensong

doi:10.3389/fphar.2020.585487

Cited by 26 publications

(12 citation statements)

References 264 publications

(373 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antimalarials have also been used to treat metabolic diseases. Chloroquine shows antihypertensive, antilipidemic, and hypoglycemic effects (11), while artemisinin and its derivatives have been used in the treatment of type 2 diabetes mellitus (17). Currently, CQ and CHQ are being tested for neurological diseases such as neurosarcoidosis, as well as chronic lymphocytic inflammation with pontine perivascular enhancement responsive to corticosteroids, and primary progressive multiple sclerosis (13).…”

Section: Clinical Applications Of Antimalarial Drugsmentioning

confidence: 99%

The Ototoxicity of Antimalarial Drugs—A State of the Art Review

Józefowicz-Korczyńska

Pajor

Grzelczyk

2021

Front. Neurol.

View full text Add to dashboard Cite

This review summarizes current knowledge about the occurrence of hearing and balance disorders after antimalarial drugs treatment. It also examines the clinical applications of antimalarials, their mechanisms behind this ototoxicity and how it can be monitored. It includes studies with larger numbers of patients and those in which auditory function was assessed using audiological tests. Some antimalarials have been repurposed for other conditions like autoimmune disorders, rheumatic diseases, some viral diseases and cancers. While old antimalarial drugs, such as quinoline derivatives, are known to demonstrate ototoxicity, a number of new synthetic antimalarial agents particularly artemisinin derivatives, demonstrate unknown ototoxicity. Adverse audiovestibular effects vary depending on the medication itself, its dose and route of administration, as well as the drug combination, treated disease and individual predispositions of the patient. Dizziness was commonly reported, while vestibular symptoms, hearing loss and tinnitus were observed much less frequently, and most of these symptoms were reversible. As early identification of ototoxic hearing loss is critical to introducing possible alternative treatments with less ototoxic medications, therefore monitoring systems of those drugs ototoxic side effects are much needed.

show abstract

Section: Clinical Applications Of Antimalarial Drugsmentioning

confidence: 99%

The Ototoxicity of Antimalarial Drugs—A State of the Art Review

Józefowicz-Korczyńska

Pajor

Grzelczyk

2021

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…For T2DM, the fasting blood glucose (FBG) level, two-hour postprandial glucose (2hPG) level, weight, and waist circumference (WC) were the main indicators ( Jiang et al, 2020 ; Hu et al, 2021 ). HbA1c represents the average blood glucose level in the preceding 3 months and was the main outcome indicator ( Altobelli et al, 2021 ; Kim and Hur, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials

Zhou

Zheng

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) prescriptions lack standardization due to the complex composition of the prescribed herbs, the unclear mechanism of the formulas, and a lack of scientific data to support the dose-response relationship. Here, we proposed a new clinical strategy of dosage modification for TCM prescriptions to evaluate the clinical efficacy and guide the clinical medication. This study used two TCM prescriptions for the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) to explore the key indications and the most appropriate critical values of dosage modification by analyzing two randomized controlled trials (RCTs). In this study, the indications refer to a change in the indicators from baseline at a certain time point (week 4, week 8, week 12), which could predict the change in outcome indicators, and the critical values refer to the change ranges closely related to the decrease in HbA1c at week 12. In Study 1, the correlation analysis between the change range of indicators at three time points (weeks 4, 8, and 12) from baseline and the decrease in HbA1c at week 12 from baseline (HbA1c 012) was carried out to screen the related indications. Next, we evaluate the related indications and the respective critical values to determine the key indicators, indications, and the most appropriate critical value. We conducted a correlation between the change range of key indicators (obtained from the result of Study 1) at three time points from baseline and HbA1c 012 to screen the key indications in the drug group, high-dose group, and low-dose group in Study 2. Key indications with critical values were determined to investigate the most appropriate critical value in the three groups separately. In Study 1, the key indicator was FBG, the key indication was FBG 04, and the most appropriate critical value was 0.5 mmol/L. In Study 2, the key indication was FBG 04 and the most appropriate critical value was 0.6 mmol/L in the drug group. In the high-dose group, the key indication was FBG 04, and the most appropriate critical value was 0.3 mmol/L. In the low-dose group, the key indication was FBG08, and the most appropriate critical value was 0.1 mmol/L. In addition, we summarized a verification strategy for dosage modification.

show abstract

“…Furthermore, Bai et al ( 2020 ) revealed the vital role of pH-dependent molecular rearrangement in the activation and activity of artemisinin against cancer. Interestingly, artemisinin and its derivatives may be valuable in treating obesity and diabetes (Shen et al 2020 ; Jiang et al 2020b ). Artemisinin can also ameliorate inflammation by suppressing the process of epithelial-mesenchymal transition and inducing macrophage polarization to the M2 phenotype, which may help treat inflammatory bowel disease in the future (Huai et al 2020 ).…”

Section: Trpcs Agonistsmentioning

confidence: 99%

Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials

et al. 2021

View full text Add to dashboard Cite

Canonical transient receptor potential channels (TRPCs) are nonselective, high calcium permeability cationic channels. The TRPCs family includes TRPC1, TRPC2, TRPC3, TRPC4, TRPC5, TRPC6, and TRPC7. These channels are widely expressed in the cardiovascular and nervous systems and exist in many other human tissues and cell types, playing several crucial roles in the human physiological and pathological processes. Hence, the emergence of TRPCs modulators can help investigate these channels’ applications in health and disease. It is worth noting that the TRPCs subfamilies have structural and functional similarities, which presents a significant difficulty in screening and discovering of TRPCs modulators. In the past few years, only a limited number of selective modulators of TRPCs were detected; thus, additional research on more potent and more selective TRPCs modulators is needed. The present review focuses on the striking desired therapeutic effects of TRPCs modulators, which provides intel on the structural modification of TRPCs modulators and further pharmacological research. Importantly, TRPCs modulators can significantly facilitate future studies of TRPCs and TRPCs related diseases.

show abstract

The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus

Cited by 26 publications

References 264 publications

The Ototoxicity of Antimalarial Drugs—A State of the Art Review

The Ototoxicity of Antimalarial Drugs—A State of the Art Review

Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials

Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials

Contact Info

Product

Resources

About